mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice

Cancer Letters

Volumn 290, Issue 2, 2010, Pages 248-254

  Hou, Guiqin ^a   Zhang, Qi ^a   Wang, Lili ^a   Liu, Mingyue ^b   Wang, Jianren ^c   Xue, Lexun ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Apoptosis; Esophageal squamous cell carcinoma (ESCC); mTOR; Rapamycin; Signaling pathway

Indexed keywords

CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 77649188319     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.09.015     Document Type: Article

References (34)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80 (1999) 827-841
2. Montesano R., Hollstein M., and Hainant P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int. J. Cancer 69 (1996) 225-235
3. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17 (2006) 487-494
4. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
5. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., and Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005) 7052-7058
6. Treeck O., Wackwitz B., Haus U., and Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gyn. Oncol. 102 (2006) 292-299
7. deGraffenried L.A., Friedrichs W.E., Russell D.H., Donzis E.J., Middleton A.K., Silva J.M., Roth R.A., and Hidalgo M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin. Cancer Res. 10 (2004) 8059-8067
8. Grünwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., and Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62 (2002) 6141-6145
9. Huang S., Liu L.N., Hosoi H., Dilling M.B., Shikata T., and Houghton P.J. p53/p21 Cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin. Cancer Res. 61 (2001) 3373-3381
10. Chakraborty S., Mohiyuddin S.M., Gopinath K.S., and Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 8 (2008) 163
11. Chan S. Targeting the mammalian target of rapamycin (mTOR); a new approach to treating cancer. Br. J. Cancer 91 (2004) 1420-1424
12. Georgakis G.V., and Younes A. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev. Anticancer Ther. 6 (2006) 131-140
13. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335-348
14. Dudkin L., Dilling M.B., Cheshire P.J., Harwood F.C., Hollingshead M., Arbuck S.G., Travis R., Sausville E.A., and Houghton P.J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7 (2001) 1758-1764
15. Asano T., Yao Y., Zhu J., Li D., Abbruzzese J.L., and Reddy S.A. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem. Biophys. Res. Commun. 331 (2005) 295-302
16. Pal S.K., Figlin R.A., and Reckamp K.L. The role of targeting mammalian target of rapamycin in lung cancer. Clin. Lung Cancer 9 (2008) 340-345
17. Hou G., Xue L., Lu Z., Fan T., Tian F., and Xue Y. mTOR/p70S6K signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 253 (2007) 236-248
18. Tian F., Zang W.D., Hou W.H., Liu H.T., and Xue L.X. Nuclear factor-kB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA. Acta. Biochim. Biophys. Sin. 38 (2006) 318-326
19. Fiebig H.H., Berger D.P., Winterhalter B.R., and Plowman J. In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts. Cancer Treat. Rev. 17 (1990) 109-117
20. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., and Gutkind J.S. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 65 (2005) 9953-9961
21. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., and Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
22. Dong M., Nio Y., Sato Y., Tamura K., Song M.M., Tian Y.L., and Dong Y.T. Comparative study of p53 expression in primary invasive ductal carcinoma of the pancreas between Chinese and Japanese. Pancreas 17 (1998) 229-237
23. Zor T., and Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal. Biochem. 236 (1996) 302-308
24. Lu Z.M., Liu H.T., Xue L.X., Xu P.R., Gong T.X., and Hou G.Q. An activated Notch1 signaling pathway inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma cell line EC9706. Int. J. Oncol. 32 (2008) 643-651
25. Han S., Khuri F.R., and Roman J. Fibronectin stimulates non small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signaling pathway. Cancer Res. 66 (2006) 315-323
26. Yoshioka A., Miyata H., Doki Y., Yasuda T., Yamasaki M., Motoori M., Okada K., Matsuyama J., Makari Y., Sohma I., Takiguchi S., Fujiwara Y., and Monden M. The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncol. Rep. 19 (2008) 1099-1107
27. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
28. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 4 (2003) 343-348
29. Abraham R.T. TOR signaling: an odyssey from cellular stress to the cell growth machinery. Curr. Biol. 15 (2005) R139-141
30. Sulis M.L., and Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 13 (2003) 478-483
31. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
32. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 4240-4245
33. Hu Y.C., Lam K.Y., Tang J.C., and Srivastava G. Mutational analysis of the PTEN/MMAC1 gene in primary esophageal squamous cell carcinomas. Mol. Pathol. 52 (1999) 353-356
34. Chang D., Wang T.Y., Li H.C., Wei J.C., and Song J.X. Prognostic significance of PTEN expression in esophageal squamous cell carcinoma from Linzhou City, a high incidence area of northern China. Dis. Esophagus 20 (2007) 491-496